Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(4):292-294; doi:10.1093/jnci/92.4.292
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nelson, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, N. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 4, 292-294, February 16, 2000
© 2000 Oxford University Press

NEWS

Experts Debate Value Of HER2 Testing Methods

Nancy J. Nelson

In spite of the 1998 Food and Drug Administration approval of Herceptin for treating advanced breast cancer patients with HER2-positive tumors, there is still a controversy about the method of choice to determine whether a tumor is HER2 positive. To air the conflicting data and hopefully come up with new strategies, the National Cancer Institute brought together more than 100 experts for a day and a half last October.

"The general conclusion was essentially that we really don’t have an ideal way to detect HER2," said Thomas Davis, Ph.D., senior investigator at NCI’s Cancer Therapeutics Evaluation Program who organized the meeting. "We need to include multiple detection methods in future trials to establish which is a superior method."

Drug and Test Development

Overexpression of the HER2 protein occurs in 25% to 30% of breast cancers and to varying degrees in other tumors. The HER2 gene is amplified in about 90% of breast tumors that . . . [Full Text of this Article]

More Discrepancies

Patient Perspective


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
B. F. Calvo, A. M. Levine, M. Marcos, Q. F. Collins, M. V. Iacocca, L. S. Caskey, C. W. Gregory, Y. Lin, Y. E. Whang, H. S. Earp, et al.
Human Epidermal Receptor-2 Expression in Prostate Cancer
Clin. Cancer Res., March 1, 2003; 9(3): 1087 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein
Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens
J. Clin. Oncol., July 15, 2002; 20(14): 3095 - 3105.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Yamauchi, V. Stearns, and D. F. Hayes
When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer
J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356.
[Abstract] [Full Text] [PDF]